文献速递脑血管病

早期微创手术治疗脑出血的成本效果分析

Cost-Effectiveness Analysis of Early Minimally Invasive Removal of Intracerebral Hemorrhage.
PubMed 文献 · Stroke · 2025-04-25

基于ENRICH随机对照试验数据,采用Markov模型比较微创经沟旁束手术(MIPS)与药物管理(MM)治疗幕上脑出血的成本效果。结果显示,在脑叶出血患者中,MIPS住院成本较MM每例少2782美元,医疗视角下MIPS每例少花费8850美元且多获得0.068个质量调整生命年,MIPS为优势策略。

要点

  • 医疗视角下MIPS每例少花费8850美元且多获得0.068个QALY,为优势策略。
  • 概率敏感性分析中MIPS在>93%的迭代中为优势策略。

核心结论

  • 在ENRICH随机对照试验中,对于脑叶出血患者,从医院和医疗视角看,MIPS较MM成本更低且更有效。

研究设计与样本

  • 基于ENRICH随机对照试验数据的Markov模型,比较MIPS与MM在6个月试验期内的成本与结局,成本为2020年美元,效果为质量调整生命年。

主要发现

  • 医疗视角下(包括医院和非医院成本),脑叶出血患者中MIPS每例较MM少花费8850美元且多获得0.068个质量调整生命年,MIPS为优势策略。

关键数值与推荐

  • MIPS设备成本为每例5705美元。
  • 主要结局为医院视角下的总住院成本,以及医疗视角下脑叶出血患者MIPS与MM的增量成本效果比(6个月成本差异除以质量调整生命年差异)。

临床怎么用

  • 对于脑叶出血患者,MIPS可能作为较MM成本更低且更有效的治疗策略。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Supratentorial intracerebral hemorrhage (ICH) is common and often devastating. In a randomized controlled trial, ICH evacuation with minimally invasive trans-sulcal parafascicular surgery (MIPS) improved functional outcomes at 180 days compared with medical management (MM), primarily in patients with lobar hemorrhages. The cost-effectiveness of MIPS compared with MM is explored. METHODS: A Markov model compared costs and outcomes using ENRICH trial (Early Minimally Invasive Removal of Intracerebral Hemorrhage) data for MIPS versus MM over the 6-month trial duration. Costs were 2020 US$ and effectiveness was quality-adjusted life years. Monthly model transitions between modified Rankin Scale score health states were estimated from trial data. Costs were obtained from US databases and literature. MIPS device costs were $5705/patient. Primary outcomes were total hospital costs from the hospital perspective and the incremental cost-effectiveness ratio between MIPS and MM (ie, the 6-month cost difference between strategies divided by quality-adjusted life year difference) from the healthcare perspective for patients with lobar ICH. Sensitivity analyses were performed. RESULTS: From the hospital perspective, MIPS costs were $2782 less per patient than MM ($74 252 versus $77 034), with MIPS having decreased the intensive care unit hospital length of stay, non-MIPS neurosurgery, mortality, and rehospitalization. From the healthcare perspective, including hospital and nonhospital costs, MIPS in lobar ICH cost $8850 less and gained 0.068 quality-adjusted life year per patient compared with MM; thus MIPS was dominant (less costly and more effective). Results were robust to individual parameter variation over plausible ranges and, with all parameters varied simultaneously in a probabilistic sensitivity analysis, MIPS was dominant in >93% of 10 000 model iterations and favored in >99% at $100 000/quality-adjusted life year gained (a common US benchmark). CONCLUSIONS: In the ENRICH randomized controlled trial, MIPS cost less and was more effective compared with MM from both hospital and healthcare perspectives for patients with lobar ICH. REGISTRATION: URL: https://clinicaltrials.gov/; Unique identifier: NCT02880878.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Hanmer J, Arnold J, Hall A, et al. Cost-Effectiveness Analysis of Early Minimally Invasive Removal of Intracerebral Hemorrhage. Stroke. 2025. PMID: 40276867. doi:10.1161/STROKEAHA.124.048493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。